Navigation Links
Inrad Optics, Inc. Announces Financial Results For First Quarter 2012

NORTHVALE, N.J., May 16, 2012 /PRNewswire/ -- Inrad Optics, Inc. (OTCBB: INRD) has released its consolidated financial results for the three months ended March 31, 2012.

Revenues for the first quarter were $2.8 million, down 12.4% from $3.2 million in the same period last year.

Orders for the first three months were $3.0 million, up from $2.7 million last year.  Order backlog increased to $5.2 million for the three months ended March 31, 2012 compared to $4.8 million for the first quarter of last year, an 8.3% increase. 

Gross profit for the quarter was 26% or $740,000 down from $873,000, or 26.9% in the comparable quarter last year.  The decrease in gross profit was attributable to lower product sales this quarter, the result of several delayed bookings anticipated in the fourth quarter 2011.

The Company ended the quarter with a net loss of $149,000, or a loss per share of $0.01 basic and diluted.  This compares to a net profit of $35,000, or earnings per share of $0.00, basic and diluted, in the same period last year.

Net cash provided by operating activities was $595,000 primarily the result of a decrease in working capital which offset the loss in the quarter.  For the comparable quarter last year, cash used by operations was $283,000, mainly reflecting the Company's payment of $300,000 against accrued interest on convertible notes payable.  Current interest of $38,000 on the convertible notes was paid in both the first quarter of 2012 and 2011, respectively.  After investing and financing activities, net cash improved by $469,000 in the three months ended March 31, 2012 and the Company ended the quarter with cash and cash equivalents of $3.9 million.  In the same quarter last year, net cash was down $302,000 and cash and cash equivalents at March 31, 2011 was $4.1 million.

Joe Rutherford, President and CEO of Inrad Optics, Inc. commented, "We were pleased with the improvement in sales and bookings and our return to profitability in 2011. Unfortunately, customer delays in placing orders in the fourth quarter of 2011 resulted in having a negative impact on product sales and financial results for the first quarter of 2012.
Bookings in the first quarter 2012 exceeded our expectations although the timing of the orders placed and the lead time required to produce the products did not allow us to ship them in the quarter. We continue to see volatility and uncertainty in customer demand in some of the markets we serve. However, with new product developments and an increasing customer base, we are confident our business climate is continuing to improve. 

"Looking ahead, I am encouraged that a number of the initiatives we began earlier last year are beginning to pay-off.  In particular, we have had promising results from our development of a new material for neutron detection and are aggressively pursuing additional funding in this area.  In addition, our recent name change to 'Inrad Optics' has been well received by our customers and delivers a more powerful branding message for our products and services."

Inrad Optics, Inc. (formerly Photonic Products Group, Inc.) was incorporated in New Jersey in 1973. In January 2012, the Company's Board of Directors and shareholders approved the name change to Inrad Optics, Inc. The Company develops, manufactures and markets products and services for use in photonics industry sectors via three distinct but complimentary product areas - "Crystals and Devices", "Custom Optics" and "Metal Optics."

The Company is a vertically integrated organization specializing in crystal-based optical components and devices, custom optical components from both glass and metal, and precision optical and opto-mechanical assemblies.  Manufacturing capabilities include solution and high temperature crystal growth, extensive optical fabrication capabilities, including precision diamond turning and the ability to handle large substrates, optical coatings and in-process metrology expertise.
Inrad Optics' customers include leading corporations in the defense, aerospace, laser systems, process control and metrology sectors of the photonics industry, as well as the U.S. Government, National Laboratories and Universities worldwide.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this press release that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These statements may be identified by their use of forward-looking terminology such as "believes", "expects", "should", "will", "plan", "anticipate", "probably", "targeting" or similar words.  Such forward-looking statements, such as our expectation for revenues, new orders, and improved results involve risks and uncertainties that could cause actual results to differ materially from those projected. Risks and uncertainties that could cause actual results to differ materially from such forward looking statements are, but are not limited to, uncertainties in market demand for the company's products or the products of its customers, future actions by competitors, inability to deliver product on time, inability to develop new business, inability to retain key employees or hire new employees, and other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission including our Annual Report on Form 10-K for the year ended December 31, 2011. The forward looking statements made in this news release are made as of the date hereof and Inrad Optics, Inc. does not assume any obligation to update publicly any forward looking statement.

 INRAD OPTICS, INC AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31,December 31,20122011(Unaudited)(Audited) AssetsCurrent assets:Cash and cash equivalents$


3,400,205Accounts receivable (net of allowance for doubtful accounts of $15,000 in 2012 and 2011)1,387,1552,052,887Inventories, net3,132,1902,909,520Other current assets117,244185,298Total current assets8,505,7338,547,910 

Plant and equipment:Plant and equipment,  at cost15,297,91015,172,428Less: Accumulated depreciation and amortization(13,770,279)(13,629,311)Total plant and equipment1,527,6311,543,117 

Precious Metals474,960474,960Deferred Income Taxes408,000408,000Goodwill311,572311,572Intangible Assets, net496,247515,888Other Assets36,55636,556Total Assets$


11,838,003Liabilities and Shareholders' EquityCurrent Liabilities:Current portion of other long term notes$


9,800Accounts payable and accrued liabilities764,349877,757Customer advances241,499266,818Total current liabilities1,015,6481,154,375Related Party Convertible Notes Payable2,500,0002,500,000Other Long Term Notes, net of current portion323,205325,633Total liabilities3,838,8533,980,008CommitmentsShareholders' Equity:Common stock: $.01 par value; 60,000,000 authorized shares; 11,868,724 shares issued at March 31, 2012 and 11,713,564 issued at December 31, 2011118,689117,137Capital in excess of par value17,931,77217,720,514Accumulated deficit(10,113,665)(9,964,706)7,936,7967,872,945Less - Common stock in treasury, at cost (4,600 shares)(14,950)(14,950)Total shareholders' equity7,921,8467,857,995 

Total Liabilities and Shareholders' Equity$


(Unaudited)Three Months EndedMarch 31,20122011Total revenue$


3,241,434Cost and expenses:Cost of goods sold2,100,7252,368,897Selling, general and administrative expenses854,289809,2452,955,0143,178,142(Loss) income from operations(114,333)63,292Other (expense) income:Interest expense—net(34,626)(32,189)Gain on sale of plant and equipment—3,626(34,626)(28,563)(Loss) income before income taxes(148,959)34,729Income tax (provision) benefit ——Net (loss) income $


34,729Net (loss) income per common share — basic and diluted$


0.00Weighted average shares outstanding  — Basic11,734,82411,579,606 

Weighted average shares outstanding
8212; diluted11,734,82411,679,990 INRAD OPTICS, INC AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)Three Months EndedMarch 31,20122011Cash flows from operating activities:Net (loss) income $


34,729Adjustments to reconcile net (loss) income to net cash provided by   (used in) operating activities:Depreciation and amortization160,609221,570401K common stock contribution151,775129,998(Gain) on sale of plant and equipment—(3,626)Stock based compensation59,68529,898Changes in operating assets and liabilities:Accounts receivable665,73299,424Inventories, net(222,670)(216,331)Other current assets68,054(87,391)Accounts payable and accrued liabilities(113,408)(61,046)Customer advances(25,319)(130,663)Accrued Interest on Related Party Convertible Notes Payable—(300,000)Total adjustments and changes744,458(318,167)Net cash provided by (used in) operating activities595,499(283,438)Cash flows from investing activities: Capital expenditures(125,482)(22,153)Proceeds from sale of plant and equipment—6,000Net cash (used in) investing activities(125,482)(16,153)Cash flows from financing activities:Redemption of restricted stock units—(370)Proceeds from exercise of stock options1,350—Principal payments of notes payable-other(2,428)(2,372)Net cash (used in) financing activities(1,078)(2,742)Net increase (decrease) in cash and cash equivalents468,939(302,333)Cash and cash equivalents at beginning of period3,400,2054,365,045Cash and cash equivalents at end of period$


4,062,712Supplemental Disclosure of Cash Flow Information:
Interest paid


341,000Income taxes paid$




SOURCE Inrad Optics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ScienceBased Health and Hoya Surgical Optics, Inc. Combine Forces to Expand Reach of Evidence-Based Nutraceuticals in Ophthalmic Market and Enhance Patient Care
2. Zyga Technology Announces $25 Million Venture Financing
3. MedClean Technologies Announces 2011 Results
4. Medical Marijuana, Inc. Announces First Quarter 2012 Results
5. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
6. Vermillion Announces CEO Succession Plan
7. Millennium Surgical Corp. Announces Sales Figures, Growth
8. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
9. IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve womens health and prenatal care
10. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
11. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Post Your Comments:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... ODH, Inc.™ announced today it will exhibit and ... Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., ... improve Medicaid population health management. , ODH will also have an exhibit booth where ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability ... Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, ... range. With color spectrum tools users can visually see the color range effected with ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... of Liberty University, has officially announced the appointment of Peter A. Bell, DO, ... of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
Breaking Medicine News(10 mins):